European Commission has granted conditional approval for CARVYKTI by Legend Biotech. The drug is intended to treat adults with relapsed and refractory multiple myeloma who have received at least three prior therapies and have demonstrated disease progression on the last therapy. The drug was approved by the FDA in February of this year.